Phase ?a Clinical Trial of a Pneumococcal Vaccine
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pneumonia
- Respiratory Tract Diseases
- Respiratory Tract Infections
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 49 years
- Gender
- Both males and females
Description
The polysaccharide vaccine protected 60% of elderly adults who were at risk for pneumococcal infection.However, pneumococci are highly diverse with respect to their capsular types , and the polysaccharide-protein conjugate vaccines will not protect against strains of the many capsular types not incl...
The polysaccharide vaccine protected 60% of elderly adults who were at risk for pneumococcal infection.However, pneumococci are highly diverse with respect to their capsular types , and the polysaccharide-protein conjugate vaccines will not protect against strains of the many capsular types not included in the vaccine.This experimental vaccine was covered 70% of all pneumococcal types, Subjects will receive three doses of PBPV vaccine on day 0,60 and 120 with different contents of 20?g,50?g,100?g each antigen in 18 to 49 years of age.
Tracking Information
- NCT #
- NCT04087460
- Collaborators
- Henan Center for Disease Control and Prevention
- Investigators
- Principal Investigator: Xia Shengli Henan Province Center for Disease Control and Prevention
Get Well Soon